demonstrated that the combination of a serum PSA measurement ≥4.0 ng/ml with other clinical findings, such as the results of a DRE, improved detection of prostate cancer in a prospective study of 1653 healthy men with no history of cancer (2). The gene discussed is KLK3; the disease is prostate carcinoma.